Related Experiment Video

Updated: Jun 2, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

FKBP38-Bcl-2 interaction: a novel link to chemoresistance

Bo-Hwa Choi1, Ho Sup Yoon

  • 1School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.

Current Opinion in Pharmacology
|May 17, 2011
PubMed

Insights

FKBP38 protein interacts with Bcl-2, enhancing its anti-apoptotic function. This interaction promotes cancer growth and chemoresistance, highlighting FKBP38 as a therapeutic target.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Immunology

Background:

  • FKBP38 is a noncanonical FKBP family member with rotamase activity.
  • FKBP38 regulates key cellular processes including apoptosis, proliferation, and metastasis.
  • Apoptosis deregulation is linked to chemoresistance and tumor recurrence.

Purpose of the Study:

  • To review recent findings on FKBP38's role in cancer.
  • To explore the interaction between FKBP38 and Bcl-2.
  • To understand the contribution of this interaction to chemotherapeutic resistance.

Main Methods:

  • Literature review of studies investigating FKBP38 and Bcl-2.
  • Analysis of signaling pathways regulated by FKBP38.
  • Discussion of molecular mechanisms underlying chemoresistance.

Main Results:

  • FKBP38 interacts with the anti-apoptotic protein Bcl-2.
  • This interaction potentiates Bcl-2's function, increasing the apoptotic threshold.
  • The FKBP38-Bcl-2 complex contributes to tumorigenesis and chemoresistance.

Conclusions:

  • FKBP38-Bcl-2 interaction is a significant factor in cancer progression.
  • Targeting FKBP38 may offer a strategy to overcome chemoresistance.
  • Further research into this pathway could lead to novel therapeutic approaches.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...